Sangamo Therapeutics (SGMO)
(Real Time Quote from BATS)
$0.93 USD
-0.03 (-3.15%)
Updated Sep 23, 2024 03:56 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Brokerage Reports
0 items in cart
Sangamo Therapeutics, Inc. [SGMO]
Reports for Purchase
Showing records 141 - 160 ( 326 total )
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; Clinical Proof-of-Concept for SB-525 in Hemophilia A
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Sangamo Acquires TxCell and CAR-Treg Technology
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials: Plenty of Cash; Wait for Clinical Efficacy Data Continues
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4 and Partnerships: Lots of Cash but Waiting for Clinical Efficacy in 2018
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
SGMO WORLDSymposium Presentations and 2018 Outlook
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Outlook: SB-525 on-track for H1:18 clinical data, Other programs delayed
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
June and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financial Update: Pfizer Deal Provides Additional Cash Runway; Reiterate NEUTRAL but Increasing PT to $6.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L